Digg icon reddit icon Stumbleupon icon
Print Email     Print Edition Stories

Wednesday, May 7, 2008

Boston Scientific gets EU OK to launch Altrua pacemaker line

By Mass High Tech

Boston Scientific Corp., a medical devices giant, has won marketing approval and plans a sales launch for its Altrua line of pacemakers in Europe, according to the company.

Natick-based Boston Scientific (NYSE:BSX) said the new pacemakers, which are implanted devices, are designed to treat a cardiac condition, known as bradycardia, that causes the heart to beat slower and deprives the body of ample oxygen.

The U.S. Food and Drug Administration has yet to approve the Altrua pacemakers and the products are not available in the United States, according to Boston Scientific.

Boston Scientific, a global developer, manufacturer and distributor of medical devices, reported a 2007 net loss of $495 million on revenue of $8.4 billion. The firm employed 27,500 workers worldwide as of December 2007.

Digg icon reddit icon Stumbleupon icon
Contact Editor Latest News

Comments

Please Login/Register to post comments.

No comments have been added or approved.

On the MHT blog now

Women’s wisdom comes back around

By Michelle Lang If you’ve ever heard the lyrics to Brad Paisley’s “Letter to Me”, you know that the country crooner made a song of taking his adult wisdom and imparting it on his 17-year-old self, reminding him not to bother arguing with his dad, to enjoy the adventure of his date with Bridget, and to thank his teacher for spending time with him. The same concept is done daily by pa...

Read More

Most Popular Stories
EmailedViewed
Stay Informed
Check which newsletter you'd like to receive.
TechFlash (Daily)
FinanceFlash (Daily)
BioFlash (Daily)
GreenFlash (Weekly)
Startup Report (Weekly)
Breaking news, MHT events, local announcements
RSS feeds
Your email:

Affiliate publications: ACBJ.com, Boston Business Journal, Bizjournals.com, Portfolio.com, Wired.com

Web Site Developed by Neptune Web, Inc.

Use of, registration on, this site constitutes acceptance of our User Agreement. Please read our Privacy Policy (updated) A publishing partner with Portfolio